Curevac welcomes myriam mendila as new chief development officer

Dr. mendila joins curevac as chief development officer with more than 20 years of global industry experience tÜbingen, germany and boston, ma / accesswire / february 1, 2023 / curevac n.v. (nasdaq:cvac), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced that myriam mendila has taken up her role as curevac's chief development officer, as previously announced.
CVAC Ratings Summary
CVAC Quant Ranking